NASDAQ:SNGX

Soligenix Stock Predictions

Healthcare > Biotechnology

Buy SNGX

*Your capital is at risk

$0.483

-0.266 (-35.48%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

SNGX Prediction Chart

SNGX Predictions History

Latest community submissions for SNGX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Dec 1, 2023	$0.92 -94.12%	$0.730	V	73.63%	1
PredictionBot.Warren Pro	Dec 1, 2023	$0.94 -93.98%	$0.730	V	70.66%	1
lewis_lawlor	Dec 1, 2023	Bullish	$0.730	X	—	0
RamboRex3000 Pro	Aug 30, 2021	$1.04 -99.56%	$0.98	X	93.55%	0
JS Pro	Aug 30, 2021	$1.03 -99.56%	$0.98	X	94.58%	0
JS Pro	Aug 30, 2021	$1.03 -99.56%	$0.98	X	94.58%	0
JimMecchella	Aug 30, 2021	Bearish	$0.98	V	—	1
garyonline321	Apr 30, 2021	Bullish	$1.44	X	—	0
JS Pro	Mar 29, 2021	$1.56 -99.56%	$1.49	V	95.30%	1
ronanmulcahy11.228342	Mar 29, 2021	Bullish	$1.49	X	—	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for SNGX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT SOLIGENIX, INC

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by